Medivir AB
Company Profile
Business description
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
Contact
Lunastigen 5
PO Box 1086, 2nd floor
Huddinge141 22
SWET: +46 854683100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
stocks
What did Morningstar subscribers buy and sell in April?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.60 | 46.70 | -0.52% |
| CAC 40 | 7,960.39 | 121.88 | -1.51% |
| DAX 40 | 24,000.70 | 455.56 | -1.86% |
| Dow JONES (US) | 49,667.31 | 396.15 | -0.79% |
| FTSE 100 | 10,186.43 | 186.50 | -1.80% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,309.44 | 325.79 | -1.22% |
| Nikkei 225 | 61,409.29 | 1,244.76 | -1.99% |
| NZX 50 Index | 12,965.01 | 60.06 | -0.46% |
| S&P 500 | 7,436.27 | 64.97 | -0.87% |
| S&P/ASX 200 | 8,630.80 | 42.70 | -0.49% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |